January 2026


Issue No. 23

LinkedIn Follow Us
 

CORNERSTONE HAPPENINGS

Our SABCS data review will be presented by Edith A. Perez, MD with Eric Schaefer, MD and Sujith Kalmadi, MD, virtually on January 22nd highlighting the key practice-changing data across breast cancer presented at SABCS 2025 in San Antonio in early December 2025. Notable studies to be discussed will include the lidERA trial in early-stage HR+ breast cancer where giredestrant a novel oral SERD outperformed long-standing endocrine agents. In HER2+ breast cancer, T-DXd (Enhertu) in combination with pertuzumab with recent FDA approval based on the DESTINY-Breast09 trial will be reviewed (FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer | FDA), while data showing that adding tucatinib to trastuzumab + pertuzumab (HP) as maintenance in HER2+ metastatic breast cancer in the HER2climb05 trial may prolong disease control and delay additional chemotherapy. In metastatic TNBC updates on quality-of-life data from the ASCENT03 and TROPION-Breast02 trials will round out this robust session. Looking forward to a great evening!

 
 

CLINICAL INVESTIGATION

We are excited to share that we will be kicking off our third Clinical Investigation study - Retrospective Chart Review to Characterize Real-World Use, Clinical Outcomes, and Safety of Datopotamab Deruxtecan (Dato-Dxd) in EGFR-Mutated NSCLC Following FDA Approval (June 23, 2025), Including Treatment Patterns and Outcomes Among Participants Eligible for Dato-Dxd sponsored by DSI at the end of January. We are looking forward to engaging with initial sites and welcome additional participation.



If interested in participating, please contact Rachel M. Condjella, Ph.D. — Senior Director of Clinical Investigations & Market Insights rcondjella@cornerstoneonc.com or Josh Ondatje — Director, Clinical Operations jondatje@cornerstoneonc.com 

We are pleased to share that our efforts toward advancing real-world oncology research continue to progress. As of January 16th, 2026 enrollment in our initial clinical investigation study, Prospective Observational Study on Infusion-Related Reactions with Docivyx® or Docetaxel in Participants with Solid Malignancies [Protocol CSNAVX1] sponsored by Avyxa has reached 93 patients across all 6 participating practices. One last push needed to close this initial clinical investigation within the month - we appreciate your efforts!



  • Ironwood – 19 patients 
  • Cancer Center of Kansas – 22 patients 
  • Northwest Cancer Centers – 23 patients  
  • Highlands Oncology Group – 13 patients 
  • Zangmeister – 10 patients 
  • Astera – 6 patients 

Our second clinical investigation study Retrospective Observational Study on HR+ and HER2-Low (IHC 1+ or 2+ with ISH negative) and HER2-Ultralow (IHC 0 with membrane staining) Metastatic Breast Cancer [Protocol CSNDSI01] sponsored by DSI has enrolled over half of needed participants with 10 active sites and 175 patients.

  • Toledo – 26 patients
  • Cancer Center of Kansas – 33 patients
  • Singing River – 20 patients
  • Zangmeister – 8 patients
  • Profound Research LLC – 6 patients
  • Premier Hematology and Oncology – 17 patients
  • HealthPartners – 30 patient
  • Northwest Cancer Center – 25 patient
  • Renown Health — 10 patients
  • Maryland Oncology — currently screening for eligible patients


As a quick reminder, this study is a retrospective study chart review and has been deemed to be IRB exempt by the Central IRB. Thanks to all who have already committed to this initiative, we look forward to filling out the remaining few open research site slots!



If interested in participating, please contact Rachel M. Condjella, Ph.D. — Senior Director of Clinical Investigations & Market Insights rcondjella@cornerstoneonc.com or Josh Ondatje — Director, Clinical Operations jondatje@cornerstoneonc.com 

Network Member Portal

Challenging Cases is a Cornerstone educational initiative exclusively for network members. Led and moderated by network oncologists. These sessions feature real-world cases, practical insights, and lessons learned from clinical practice. This is a valuable opportunity to learn from your peers, exchange perspectives, and engage in active discussion throughout the program.


Log in to the network portal to explore the recently posted past Challenging Cases and learn from peer-led discussions.

Your News, Our Newsletter!

We want to hear from you! Share your exciting projects, upcoming events, or personal milestones with the Cornerstone Specialty Network community.

2026 UPCOMING EVENTS

Cornerstone Specialty Network's Strategic Advisor National Summit will be held in Scottsdale, AZ in March 2026 - look forward to seeing you there!

We are looking forward to our ASH 2026 Data Review to be held virtually on February 19th, 2026 co-chaired Dr. Pankit Vachhani with Dr. Sujith Kalmadi and Dr. Eric Schaefer! Click below to join the waitlist.

CLINICAL UPDATES

FDA Updates for December 2025


Oncology (Cancer)/Hematologic Malignancies Approval Notifications | FDA 


On December 17, 2025, the FDA approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.) evaluated in PALOMA-3 trial. Read More


On December 17, 2025, the FDA approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy evaluated in TRITON3. Rucaparib was granted accelerated approval in 2020 for a similar indication. Read More


On December 15, 2025, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test evaluated in the DESTINY-Breast09 trial. FDA also approved the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and HER2 Dual ISH DNA Probe Cocktail as companion diagnostic devices for selecting HER2-positive (HER2 IHC3+ or ISH+) breast cancer patients for treatment with fam-trastuzumab deruxtecan-nxki in combination with pertuzumab.  Read More


On December 12, 2025, the FDA approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test evaluated in AMPLITUDE. Read More


On December 4, 2025, the FDA approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy based

on the TRANSCEND FL-MZL trial. Read More


On December 3, 2025, the FDA granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory CLL/SLL who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor evaluated in BRUIN-CLL-321. Read More

Thank You

Cornerstone would like to take this opportunity to thank our select pharma partners for their support of our programs enabling us to provide unique opportunities to connect with our network, deliver key educational programs, and ultimately benefit patient care. 

The largest and most diverse

Independent Network in Community Oncology.

Do you want to be updated on our network news and initiatives in a simple and fast way?

Follow the Cornerstone Specialty Network page on LinkedIn

Click here to follow our page!

 

Cornerstone Specialty Network LLC  •  P.O. Box 173, New Hope, PA


www.cornerstoneoncology.com